Cart
sales@molnova.com
IL-17A inhibitor 1
CAS No. 2452464-73-0
IL-17A inhibitor 1( —— )
Catalog No. M28693 CAS No. 2452464-73-0
IL-17A inhibitor 1 (example 24) is an inhibitor of IL-17A.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 4369 | In Stock |
|
| 5MG | 1764 | In Stock |
|
| 10MG | 2713 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIL-17A inhibitor 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionIL-17A inhibitor 1 (example 24) is an inhibitor of IL-17A.
-
DescriptionIL-17A inhibitor 1 (example 24) is an inhibitor of IL-17A.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetIL Receptor
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2452464-73-0
-
Formula Weight586.524
-
Molecular FormulaC24H27F5N8O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (426.25 mM)
-
SMILESCOC[C@@H](N1C[C@H](NC1=O)C(F)(F)F)c1cnn2cc(nc2c1)[C@@H](NC(=O)c1nonc1C)C1CCC(F)(F)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bao B, et al. Monoindole alkaloids from a marine sponge Spongosorites sp. Mar Drugs. 2007 Jun 25;5(2):31-9.
molnova catalog
related products
-
Dersalazine
Dersalazine (Dersalazine Free Base), an inhibitor of platelet-activating factor, exerts intestinal anti-inflammatory activity in different rodent types of colitis by down-regulating IL-17 expression, with potential efficacy in patients with ulcerative colitis.
-
GSK717
GSK717 is a potent and selective inhibitor of nucleotide-binding oligomerization domain 2 (NOD2). GSK717 blocks synergy between NOD2 and TLR2. GSK717 does not affect NOD1, TNFR1 and TLR2-mediated responses.
-
Spesolimab
Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. It plays a crucial role in the immune system by reducing biomarkers associated with congenital Th1/Th17 and neutrophil pathways.
